Company intelligence / Profile preview

Avraham Pharmaceuticals Ltd.

Yavneh, Central District, Israelavphar.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Avraham Pharmaceuticals has completed a Phase 2b clinical trial for ladostigil for the treatment of mild cognitive impairment (MCI). The second interim results showed a positive trend in the ladostigil-treated group compared to placebo in preventing progression from MCI to Alzheimer's disease. The drug also showed statistically significant protection against loss of whole brain volume as measured by MRI and demonstrated an excellent safety profile.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ladostigil

Partnerships

Teva Pharmaceutical Industries Ltd.

Beyond the preview

Go deeper on Avraham Pharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avraham Pharmaceuticals Ltd..